Issues relating to rare disease and patient access.
2026 · 2nd Quarter (Apr 1 - June 30)
ULTRAGENYX PHARMACEUTICAL, INC.
Filed by MEHLMAN CONSULTING, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- MEHLMAN CONSULTING, INC.
- Filing UUID
- d9d28e4e-2395-49a5-9b5b-be971ebe8eba
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
FY27 Appropriations (H.R.8646, Agriculture, Rural Development, Food and Drug Administration)
Literal federal measure citations: H.R.8646
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.